SCHEMBL27162298

SCHEMBL27162298

CC(C)(C)CCN1CCC2(CCCN(S(=O)(=O)c3ccc(Cl)nc3)C2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.51
▸ CYP2D6 P10635 10/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ TSHR P16473 6/20 0.46
▸ CYP3A4 P08684 10/20 0.45
▸ CYP1A2 P05177 8/20 0.45
▸ USP2 O75604 4/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ XBP1 P17861 1/20 0.39
▸ OPRM1 P35372 1/20 0.39
▸ OPRD1 P41143 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27162691 0.89 TSHR (0.46) CYP2D6ALDH1A1TSHRCYP3A4CYP1A2
SCHEMBL30049578 0.89 TSHR (0.46) CYP2D6ALDH1A1TSHRCYP3A4CYP1A2
SCHEMBL27162956 0.89 ALDH1A1 (0.57) POLBCYP2D6ALDH1A1TSHRCYP3A4
SCHEMBL30050265 0.88 CYP3A4 (0.46) CYP2D6ALDH1A1TSHRCYP3A4CYP1A2
SCHEMBL27161860 0.88 CYP3A4 (0.46) CYP2D6ALDH1A1TSHRCYP3A4CYP1A2
SCHEMBL30049872 0.87 TSHR (0.45) CYP2D6ALDH1A1TSHRCYP3A4CYP1A2
SCHEMBL30049764 0.87 TSHR (0.45) CYP2D6ALDH1A1TSHRCYP3A4CYP1A2
SCHEMBL27162655 0.87 TSHR (0.45) CYP2D6ALDH1A1TSHRCYP3A4CYP1A2
SCHEMBL27162034 0.87 TSHR (0.45) CYP2D6ALDH1A1TSHRCYP3A4CYP1A2
SCHEMBL30051180 0.86 TSHR (0.44) CYP2D6ALDH1A1TSHRCYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 POLB 3197/4885CYP2D6 514/4885ALDH1A1 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback